No Data
No Data
Mengke Pharmaceutical (688373.SH): intends to continue using temporarily idle raised funds of no more than 0.5 billion yuan for cash management.
On August 6th, Gelonghui reported that Mengke Pharmaceuticals (688373.SH) intends to continue using temporarily idle raised funds not exceeding RMB 0.5 billion (including principal) for cash management, with a single maximum term not exceeding 12 months, and valid within 12 months from the date of approval by the company's board of directors. Within the above-mentioned amount and validity period, the funds can be rolled over and used.
Mengke Pharmaceuticals showcased innovative antibiotic research results at the Seventh World Bronchiectasis Conference.
At the 7th World Bronchiectasis Conference, Minkang Pharmaceuticals showcased the latest research progress of its pipeline products MRX-8 and MRX-5. Three important research results further support the potential of MRX-8 and MRX-5 in treating non-tuberculosis mycobacterial lung disease and Pseudomonas aeruginosa infection. Dundee, Scotland, July 17, 2024 /PRNewswire/ - Shanghai Minkang Pharmaceutical Co., Ltd. ("Minkang Pharmaceuticals", 688373.SH) held at the 7th World Bronchiectasis Conference from July 4 to July 6, 2024 in Dundee, Scotland.
Mengke Pharmaceuticals (688373.SH): 13.4044 million shares of the first public offering of restricted shares will be listed and traded on July 15th.
Mengke Pharmaceutical Co., Ltd. (688373.SH) announced that the stock will be listed as initial restricted shares. The stock subscription party...
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
MicuRx Pharma's Phase 1 China Trial for Polymyxin Antibiotic Shows Good Safety Profile
Mengke Pharmaceutical: The Phase I clinical trial of the independently developed antimicrobial drug MRX-8 in China has been successfully completed.
According to data from the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening situations due to drug-resistant infections every year. MRX-8 not only performs well in terms of safety and tolerance, but also demonstrates strong antibacterial activity against multidrug-resistant gram-negative bacteria, with significant clinical application potential. In China, the total number of days of antibiotic treatment for multidrug-resistant gram-negative bacterial infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3% during this period. Shanghai, June 5, 2024 / PRNewswire/ -
No Data